🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Edinburgh
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Edinburgh

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca34 Merck Sharp & Dohme LLC15 Janssen Research & Development, LLC13 AbbVie10 Hoffmann-La Roche9
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
254 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910Crohn's Disease
Takeda
Phase 3
396
London, Edinburgh, Glasgow
2025-01-02
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604Graves' Disease
Immunovant Sciences GmbH
Phase 2
240
Birmingham, Bristol, Coventry, London, Cambridge, Cardiff, Edinburgh, Huddersfield
2024-12-17
Active, closed
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT06627179Retinitis Pigmentosa (RP), Usher Syndrome Type 2, Deaf Blind, Retinal Disease
Laboratoires Thea
Phase 2
81
Headington, Edinburgh, London
2024-12-11
Recruiting
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
NCT06603844Solid Tumor
Corbus Pharmaceuticals Inc.
Phase 1/2
156
Newcastle upon Tyne, Manchester, Birkenhead, Edinburgh, Glasgow, London
2024-12-04
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647Non-squamous Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-27
Active, closed
Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine
NCT06543914Migraine
AbbVie
Observational
1,314
Hull, Edinburgh, London, Nottingham, Stoke-on-Trent, Leeds, Swindon, Worcester
2024-11-26
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738Non-small Cell Lung Cancer
AstraZeneca
Phase 3
1,160
Aberdeen, Cambridge, Edinburgh, Exeter, Greater London, London, Manchester, Newcastle upon Tyne
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Endeavor Biomedicines, Inc.
Phase 2
213
Belfast, Birmingham, Cambridge, Edinburgh, Exeter, Leicester, London, Londonderry
2024-11-15
Recruiting
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors
NCT06619587Solid Tumor
Genentech, Inc.
Phase 1
410
Edinburgh, London, Manchester, Sutton
2024-11-14
Active, closed
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153Alzheimer's Disease
Eli Lilly and Company
Phase 3
1,400
Bath, Birmingham, Blackpool, Edinburgh, London, Manchester, Motherwell, Plymouth
2024-10-24
Active, closed
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer
Phase 3
600
Blackburn, Westcliff-on-Sea, Edinburgh, Glasgow, London, Metropolitan Borough of Wirral, Swansea
2024-10-21
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786Colorectal Neoplasms
Janssen Research & Development, LLC
Phase 3
1,000
Birmingham, Cambridge, Edinburgh, Hull, Leeds, London, Northwood, Sutton
2024-10-18
Recruiting
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142Neoplasms
GlaxoSmithKline
Phase 1
845
Edinburgh, Glasgow, London, Manchester, Newcastle upon Tyne
2024-09-30
Recruiting
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
NCT05663515Pancreatic Cancer
AstraZeneca
Observational
24,000
Edinburgh, London
2024-09-30
Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
NCT06559150Non-cystic Fibrosis Bronchiectasis
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Phase 2
284
Dundee, Glasgow, Birmingham, Belfast, Cambridge, Edinburgh, Liverpool, London
2024-09-11
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
AbbVie
Phase 2
540
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Recruiting
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
NCT06547840Advanced Ovarian Cancer, Platinum-resistant Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Triple -Negative Breast Cancer
Epsilogen Ltd
Phase 1
45
Bristol, Edinburgh, Leeds, London, Southampton
2024-09-03
Active, closed
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302Lymphoma, Follicular
Celgene
Phase 2
95
Southampton, Canterbury, Edinburgh, Nottingham
2024-08-30
Active, closed
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT06449222Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
BioNTech SE
Phase 2
83
Cottingham, Edinburgh, Leeds, London
2024-08-26
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
AbbVie
Phase 3
110
Cambridge, Sheffield, London, Norwich, Edinburgh
2024-08-08
Active, closed
A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease
NCT06544616Alzheimer Disease
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth
2024-07-22
Recruiting
A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial
NCT06521047Acute Myocardial Infarction
CellProthera
Observational
48
Dundee, Edgbaston, Edinburgh, London
2024-07-20
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
Jazz Pharmaceuticals
Phase 3
286
London, Manchester, Surrey, Edinburgh
2024-07-19
Active, closed
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202Chronic Spontaneous Urticaria
Celldex Therapeutics
Phase 3
976
Bristol, Cambridge, Edinburgh, Glasgow, High Wycombe, Leeds, London, North Finchley
2024-07-19
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
136
Edinburgh, London, Manchester, Oxford
2024-07-09
Rows per page Showing 76–100 of 254
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/edinburgh

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.